IQVIA (NYSE:IQV) & Absci (NASDAQ:ABSI) Critical Comparison
IQVIA (NYSE:IQV – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.
Valuation and Earnings
This table compares IQVIA and Absci’s gross revenue, earnings per share (EPS) and valuation.
| Gross revenue | Price/sales ratio | Net Income | Earnings Per Share | Price/earnings ratio | |
| IQVIA | $13.87 billion | 2.92 | $966.00 million | $5.55 | 38.53 |
| absci | $4.78 million | 94.52 | -$100.96 million | N / A | N / A |
IQVIA has higher revenue and earnings than Absci.
profitability
This table compares IQVIA and Absci’s net margins, return on equity and return on assets.
| net margins | return on equity | return on assets | |
| IQVIA | 7.69% | 28.80% | 6.95% |
| absci | -2,111.25% | -52.14% | -20.44% |
Analyst Ratings
This is a summary of current ratings and target prices for IQVIA and Absci, as reported by MarketBeat.
| sell ratings | hold ratings | Buy rating | Strong Buy Ratings | rating score | |
| IQVIA | 0 | 1 | 15 | 0 | 2.94 |
| absci | 1 | 3 | 3 | 0 | 2.29 |
IQVIA currently has a consensus price target of $280.21, indicating a potential upside of 31.05%. Absci has a consensus price target of $24.00, indicating a potential upside of 392.81%. Given Absci’s higher probable upside, analysts plainly believe Absci is more favorable than IQVIA.
Insiders & Institutional Ownership
87.1% of IQVIA shares are held by institutional investors. Comparatively, 40.0% of Absci shares are held by institutional investors. 1.3% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
IQVIA beats Absci on 9 of the 11 factors compared between the two stocks.
IQVIA Company Profile (Get Rating)
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care providers and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Absci Company Profile (Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for IQVIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IQVIA and related companies with MarketBeat.com’s FREE daily email newsletter.